Biogen Q2 2026 Results: Revenue Beat, EPS Cut

Biogen’s Q2 2026 results on July 29 showed a revenue beat as newer drugs and the May Apellis acquisition offset declines in legacy multiple sclerosis (MS) sales, even as the company lowered its full-year adjusted EPS guidance.

Quarter Results and Guidance

Biogen Inc. reported total revenue of $2.7 billion for Q2 2026, up 3.0% year over year. Adjusted diluted EPS was $3.60, down about 34.0% from the prior year but above analyst estimates. The company raised its 2026 revenue outlook to a mid-single-digit percentage increase, reversing earlier guidance for a decline. However, it lowered full-year adjusted EPS guidance to a range of $12.00 to $13.00, down from prior forecasts between $14.25 and $16.25. The revision reflects acquisition-related charges and ongoing research and development expenses.

Growth Portfolio and Apellis Acquisition

Biogen’s Growth Portfolio generated $1.1 billion in revenue, rising 24.0% year over year and surpassing the legacy MS business for the first time. LEQEMBI, the Alzheimer’s drug co-developed with Eisai, posted global sales of $184 million, up 15.0% from a year earlier.

The May 2026 acquisition of Apellis Pharmaceuticals contributed significantly in its first full quarter. Syfovre, an ophthalmology treatment, added $97 million, and Empaveli, a rare-disease drug, contributed $30 million, both exceeding expectations. These products expanded Biogen’s rare-disease and ophthalmology portfolio, supporting management’s goal of sustainable revenue growth.

Product Performance and Legacy MS

Among newer medicines, Skyclarys generated $168 million, above consensus estimates. Qalsody more than doubled year over year with $32–$33 million in sales. Zurzuvae delivered about $55 million, with inventory factors limiting sequential growth. Spinraza, for spinal muscular atrophy, rose 7.0% sequentially to $402 million.

In contrast, the legacy MS franchise declined 13.0% year over year to $963 million. Ocrevus royalties from Roche accounted for $381 million of that total.

Cash Flow and Deal-Related Charges

Biogen posted $408 million in free cash flow for the quarter, with cash balances of $1.3 billion and net debt of approximately $6.8 billion at quarter-end. The free-cash-flow margin improved to 17.9% from 5.1% a year earlier.

The results included about $164 million in acquired in-process research and development (IPR&D) and related upfront and milestone expenses tied to the Apellis acquisition. Both GAAP and adjusted earnings reflect dilution from the deal and ongoing Phase 3 investments. Analysts estimate these acquisition-related charges reduced EPS by roughly $3.85 per share, a key factor in the lowered full-year adjusted EPS guidance.

Strategic Outlook

Biogen’s management described the quarter as evidence of a structural shift in revenue mix. Growth now comes primarily from newer and rare-disease medicines, including recently acquired products, while older MS franchises continue to decline. The company highlighted ongoing pipeline programs, such as high-dose Spinraza and advancing antibody assets, as drivers for medium-term growth. Analysts note this quarter may mark an inflection point toward revenue stabilization, but sustained momentum from newer products will be necessary over several years to fully offset MS erosion and restore adjusted earnings.

Biogen said the results “demonstrate progress toward its goal of sustainable revenue growth.”